Genocide Europe 2025:
COVID-19 Vaccination in the United Kingdom (to June 2021)
41,551,201 people have received one vaccine dose.
29,792,658 people have received both vaccine doses.
(Infertility, Global Depopulation & Transhumanism)
Section 21 – AstraZeneca
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It is perhaps best known for its involvement in developing the Oxford-Astrazeneca COVID-19 vaccine.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world’s largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden and Gaithersburg in Maryland, U.S.
AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on Nasdaq OMX Stockholm, Nasdaq New York, the Bombay Stock Exchange and on the National Stock Exchange of India.
Oxford–AstraZeneca COVID-19 vaccine
The Oxford–AstraZeneca COVID-19 vaccine, codenamed AZD1222, and sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for prevention of COVID-19. Developed by Oxford University and AstraZeneca, it is given by intramuscular injection, using as a vector the modified chimpanzee adenovirus ChAdOx1. The efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. Another analysis showed that, for symptomatic COVID-19 infection after the second dose, the vaccine is 66% effective against B.1.1.7 (alpha) variant, and 60% against B.1.617.2 (delta) variant.
The vaccine has a good safety profile, with side effects including injection-site pain, headache, and nausea, all generally resolving within a few days. More rarely, anaphylaxis may occur (the UK Medicines and Healthcare products Regulatory Agency (MHRA) has 268 reports out of some 21.2 million vaccinations as of 14 April 2021). In very rare cases (around 1 in 100,000 people) the vaccine has been associated with an increased risk of blood clots in combination with low levels of blood platelets. According to the European Medicines Agency as of 4 April 2021, 222 cases of blood clots have been reported from the European Economic Area and the UK, where around 34 million people have received the vaccine.
On 30 December 2020, the vaccine was first approved for use in the UK vaccination programme, and the first vaccination outside of a trial was administered on 4 January 2021. The vaccine has since been approved by several medicine agencies worldwide, such as the European Medicines Agency (EMA), and the Australian Therapeutic Goods Administration, and was approved for an Emergency Use Listing by the World Health Organization (WHO). Some countries have limited its use to elderly people at higher risk for severe COVID-19 illness due to concerns over the very rare side effects of the vaccine in younger individuals.
HALT ALL COVID-19 VACCINE ROLLOUTS
CDC UPDATED: 1,524 DEAD 31,079 INJURED FOLLOWING EXPERIMENTAL COVID MRNA ‘VACCINES’
Source: Humans Are Free – March 17, 2021
The CDC added more data today into the Vaccine Adverse Event Reporting System (VAERS), a U.S. Government funded database that tracks injuries and deaths caused by vaccines.
Besides the recorded 1,524 deaths, there were 5,806 visits to Emergency Room doctors, 630 permanent disabilities, and 3,477 hospitalizations.
The CDC also updated their Selected Adverse Events Reported after COVID-19 Vaccination page on March 9th this past week, and according to this report, VAERS has received 1,637 reports of death following COVID “vaccinations” – more than 100 deaths than are in the VAERS data dump released today.
The CDC continues to state that not one of these recorded deaths following experimental COVID injections are related to the shots.
“A review of available clinical information including death certificates, autopsy, and medical records revealed no evidence that vaccination contributed to patient deaths.” (Source)
AstraZeneca COVID Vaccine Inoculations Halted In Many Countries Due To Fatal Blood Clots
As we reported yesterday, many countries in Europe (and now also Thailand) have halted the vaccinating of people with the AstraZeneca experimental vaccine after reports of fatal blood clots following the injections.
And while the AstraZeneca COVID shots are not yet authorized for emergency use in the U.S., some have commented that the side effects for the mRNA “vaccines” currently issued EUAs in the U.S. for Pfizer and Moderna have just as many, if not more, adverse side effects, questioning whether any of these new experimental and non-FDA-approved COVID vaccines should be continued.
So we searched today’s CDC data on adverse reactions to the two COVID “vaccines” being used in the U.S. for “pulmonary embolism,” which is an “acute lung disease caused by a dislodged blood clot,” and the reason why the AstraZeneca COVID shot is now being halted in about a dozen countries worldwide after two fatalities and others injured.
This number is obviously far greater than the two deaths reported so far from pulmonary embolism following the AstraZeneca COVID shots being distributed around the world right now.
NO BLACK SUN VACCINE!
A false flag is a covert operation designed to deceive; the deception creates the appearance of a particular party, group, or nation being responsible for some activity, disguising the actual source of responsibility.
Photographic & Promotional Subliminals
Oxford–AstraZeneca COVID-19 vaccine authorizations
The Oxford–AstraZeneca COVID-19 vaccine, sold under the brand names Vaxzevria and Covishield, is a viral vector vaccine produced by the British University of Oxford, British-Swedish company AstraZeneca, and the Coalition for Epidemic Preparedness Innovations. Two countries, Denmark and Norway, permanently halted the use of the Oxford–AstraZeneca vaccine due to a small number of reports of a rare blood clot disorder.
- Bosnia and Herzegovina
- Burkina Faso
- Cape Verde
- Central African Republic
- Congo, DR
- Congo, Rep. of the
- Costa Rica
- Dominican Republic
- East Timor
- El Salvador
- Ivory Coast
- New Zealand
- North Macedonia
- Papua New Guinea
- Sao Tome and Principe
- Saudi Arabia
- Sierra Leone
- Solomon Islands
- South Korea
- South Sudan
- Sri Lanka
- United Arab Emirates
- United Kingdom
European Economic Area countries
CARPHA (Caribbean Public Health Agency) countries
- Antigua and Barbuda
- Saint Kitts and Nevis
- Saint Lucia
- Saint Vincent and the Grenadines
- Trinidad and Tobago
CARPHA non-country entities
- British Virgin Islands
- Caribbean Netherlands
- Cayman Islands
- Sint Maarten
- Turks and Caicos Islands
Other non-country entities
- Cook Islands
- Falkland Islands
- French Polynesia
- Isle of Man
- Northern Cyprus
- Saint Helena, Ascension and Tristan da Cunha
- Wallis and Futuna